XALKORI is used to treat rare types of lung cancer.
If it does not work, Pfizer will refund some monies.
There is a possibility of having other adverse effects including death, permanent vision loss, Bradycardia etc.
Pfizer should pledge a warranty for ALL their vaccines!
As part of its commitment, Pfizer is proud to offer the Pfizer Pledge Warranty Program for XALKORI (the “Program”
.*
With the Program, eligible patients can get their out-of-pocket costs for XALKORI refunded.
Overview of Program
For Patients who meet the Eligibility Requirements, Pfizer will refund the out-of-pocket amount that you paid for up to the first three (3) bottles (30-day supply) of Xalkori, up to a maximum of $19,609 for each bottle (30-day supply) or an aggregate maximum of up to $58,827 (the “Maximum”
.
XALKORI
IMPORTANT SAFETY INFORMATION
(Snippets taken from official documents, sounds familiar to covid vaccines)
DEATH
Hepatotoxicity: Drug-induced hepatotoxicity with fatal outcome occurred in 0.1% of patients treated with XALKORI across clinical trials (n=1719).
Increased transaminases generally occurred within the first 2 months. transaminases.
LUNG DISEASE
Interstitial Lung Disease/Pneumonitis: Severe, life-threatening, or fatal interstitial lung disease (ILD)/pneumonitis can occur. Across clinical trials (n=1719), 2.9% of XALKORI-treated patients had any grade ILD, 1.0% had Grade 3/4, and 0.5% had fatal ILD. ILD generally occurred within 3 months after initiation of treatment.
QT Interval Prolongation:
QTc prolongation can occur. Across clinical trials (n=1616), 2.1% of patients had QTcF (corrected QT by the Fridericia method)
Bradycardia: Symptomatic bradycardia can occur. Across clinical trials, bradycardia occurred in 13% of patients treated with XALKORI (n=1719).
BLINDNESS
Severe Visual Loss: Across clinical trials, the incidence of Grade 4 visual field defect with vision loss was 0.2% of 1719 patients. Optic atrophy and optic nerve disorder have been reported as potential causes of visual loss.
Vision Disorders:
Most commonly visual impairment, photopsia, blurred vision or vitreous floaters occurred in 63% of 1719 patients.
Embryo-Fetal Toxicity: XALKORI can cause fetal harm when administered to a pregnant woman.
Adverse Reactions: Serious adverse events were reported in 34% of patients treated with XALKORI, the most frequent were dyspnea (4.1%) and pulmonary embolism (2.9%). Fatal adverse events in XALKORI-treated patients occurred in 2.3% of patients, consisting of septic shock, acute respiratory failure, and diabetic ketoacidosis.
